{
    "clinical_study": {
        "@rank": "89122", 
        "acronym": "MEDIAGENE", 
        "arm_group": {
            "arm_group_label": "Mediagene", 
            "arm_group_type": "Other", 
            "description": "Sampling blood"
        }, 
        "brief_summary": {
            "textblock": "More than 5 million persons in France exposed, in last years, to the taking of the\n      Benfluorex.\n\n      Arisen, at certain patients, of a valvulopathy characterized by mitrals and/or aortic leaks\n      Withdrawal of the French market: nov. 2009 Only a percentage limited by exposed patients\n      developed a severe valvulopathy (1/1000), whereas on the contrary, many patients were\n      exposed during years without developing the slightest anomaly.\n\n      The hypothesis is the existence of a particular genetic susceptibility at the patients\n      having developed a valvulopathy continuation in the exposure in this medicine.\n\n      Existence of one varying genetics with strong effect. The purpose is to identify involved\n      genetic factors."
        }, 
        "brief_title": "Study of the Effect of the Benfluorex", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Sampling of Blood", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria of the cases :\n\n          -  Individual presenting a typical medicinal valvulopathy defined by:\n\n          -  A previous exposure of at least 6 months in the benfluorex or occasional exposure\n             accepted about is the posology. The preliminary exposure in the dexfenfluramine or in\n             the fenfluramine is authorized.\n\n          -  A picture board of insufficiency mitral restrictive and/or aortic restrictive (in\n             echocardiography) typical of a medicinal achievement, an average gravity in severe\n             (rank II - IV), without cause associated of valvulopathy (no calcification, no\n             atypical aspect) with compatible macroscopic and histological aspect (for the\n             operated patients).\n\n          -  Individual followed in one of the sites of study or recruited via associations AVIM\n             and CADUS.\n\n          -  Individual of Caucasian origin\n\n          -  Individual having signed the form of specific consent for the study individual .\n\n        Inclusion criteria of witnesses :\n\n          -  Individual presenting an exposure previous to the benfluorex superior or equal to the\n             equivalent of 2 years of treatment in 3 tablets a day and pursued to 2 years\n             preceding the realization of a cardiac echography of screening. The preliminary\n             exposure in the dexfenfluramine or in the fenfluramine is authorized.\n\n          -  Individual presenting a strictly normal cardiac echography in particular: absence of\n             valvulopathy significant, of morphological valvular anomaly (event without\n             echography) and of valvular, including \"trivial\" leak at the aortic level. The\n             mitrals micro leaks \"physiological\" are accepted.\n\n          -  Individual having been seen for screening in one of the sites of study or having been\n             included in the forward-looking study coordinated by Pr. TRIBOUILLOY (which the\n             objective is to compare the echography data of a group of patients having been\n             treated at least 3 months in the benfluorex and with a group of patients diabetics\n             having never received this medicine).\n\n          -  Individual of Caucasian origin.\n\n          -  Individual having signed the form of specific consent for the study\n\n        Exclusion criteria of the cases:\n\n          -  Individual presenting another associated heart disorder.\n\n          -  Individual having been exposed to another agonists of the receivers 5-HT2B such as\n             the pergolide, the cabergoline, the lisuride, the quibbled by-products or the\n             ecstasy.\n\n          -  Individual having explicitly refused to participate in the study.\n\n        Exclusion criteria of witnesses :\n\n        - Individual having explicitly refused to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008552", 
            "org_study_id": "MEDIAGENE"
        }, 
        "intervention": {
            "arm_group_label": "Mediagene", 
            "description": "Sampling of blood was taken and analyse to research factor genetic", 
            "intervention_name": "Sampling of blood", 
            "intervention_type": "Genetic"
        }, 
        "intervention_browse": {
            "mesh_term": "Benfluorex"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Genetic factor", 
            "Valvulopathy", 
            "Mediator"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Christophe Tribouilloy, PUPH"
                }, 
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "zip": "80054"
                    }, 
                    "name": "H\u00f4pital Sud Amiens"
                }, 
                "investigator": {
                    "last_name": "Christophe Tribouilloy, PUPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ir\u00e8ne FRACHON, PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France", 
                        "zip": "29200"
                    }, 
                    "name": "CHRU de Brest"
                }, 
                "investigator": [
                    {
                        "last_name": "Ir\u00e8ne FRACHON, PH", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yannick Jobic, PH", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Yves Etienne, PH", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14033"
                    }, 
                    "name": "CHU de la C\u00f4te de Nacre Caen"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Atul Pathak, PUPH"
                }, 
                "facility": {
                    "address": {
                        "city": "France", 
                        "country": "France", 
                        "zip": "31073"
                    }, 
                    "name": "Facult\u00e9 de m\u00e9decine Toulouse"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Louis Montastruc, PUPH", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Atul Pathak, PUPH", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gilbert Habib, PUPH"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "H\u00f4pital La Timone Marseille"
                }, 
                "investigator": {
                    "last_name": "Gilbert Habib, PUPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Pierre Gueffet, PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Institut du Thorax Nantes"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Pierre Gueffet, PH", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Thierry Letrourneau, puph", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Research for Genetic Factors Involved in the Individual Susceptibility to Develop a Valvulopathy During a Medicinal Exposure in the Benfluorex.", 
        "overall_contact": {
            "email": "patricia.brize@chu-brest.fr", 
            "last_name": "Patricia Brize"
        }, 
        "overall_contact_backup": {
            "email": "irene.frachon@chu-brest.fr", 
            "last_name": "Ir\u00e8ne Frachon, PH"
        }, 
        "overall_official": {
            "affiliation": "CHRU de Brest", 
            "last_name": "Ir\u00e8ne Frachon, PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Identify the genetic factors involved in the individual susceptibility to develop a valvulopathy during a medicinal exposure in the benfluorex.", 
            "measure": "Identify the genetic factors", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Compare the quality of life of the cases and the witnesses via the completion of Two validated questionnaires of quality of life.", 
            "measure": "Compare the quality of life", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "University Hospital, Brest", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, France", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Brest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}